{
    "2018-09-24": [
        [
            {
                "time": "2018-03-15",
                "original_text": "J&J's Esketamine Fails to Meet Endpoint in Phase III Study",
                "features": {
                    "keywords": [
                        "Esketamine",
                        "Phase III",
                        "fails",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "J&J Talc Cancer Case Ends in Mistrial With Divided Jury",
                "features": {
                    "keywords": [
                        "Talc",
                        "Cancer",
                        "Mistrial",
                        "Divided Jury",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Why Geron Corporation Stock Is Bolting Higher Today",
                "features": {
                    "keywords": [
                        "Geron Corporation",
                        "Stock",
                        "Bolting",
                        "Higher"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-12",
                "original_text": "AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Diabetes",
                        "Treatment",
                        "Cardiovascular",
                        "Risk"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-05",
                "original_text": "AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Diabetes",
                        "Treatment",
                        "Cardiovascular",
                        "Risk"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-15",
                "original_text": "Johnson & Johnson Might Be Tempted to Buy These 2 Device Makers",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Device Makers",
                        "Buy"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}